Cytokines and cancer

International Reviews of Immunology

Volumn 16, Issue 5-6, 1998, Pages 683-704

  Tartour, E ^a   Fridman, W H ^a  

^a INSTITUT CURIE   (France)

Author keywords

Cancer; Cytokine; Immunotherapy; Prognostic marker

Indexed keywords

EID: 0031831156     PISSN: 08830185     EISSN: None     Source Type: Journal    
DOI: 10.3109/08830189809043014     Document Type: Article

References (130)

1. Sugarman, B.J., Aggarwal, B.B., Hass, P.E., Figari, I.S., Pallidino, M.A. Jr. and Shepard, H.M. Recombinant human tumor necrosis factor alpha effects on proliferation of normal and transformed cells in vitro. Science, 230, 943-945, 1985.
2. Urabe, A. Interferons for the treatment of hematological malignancies. Oncology, 51, 137-141, 1994.
3. Topp, M.S., Papadimitriou, C.A., Eitelbach, F., Oelman, E., Koehler, B., Oberberg, D., Von Marschall, Z., Reufi, B., Stein, H. and Thiel, E. Leuk. Lymph., 19, 319-328, 1995.
4. Toi, M., Bicknell, R. and Harris, A.L. Inhibition of colon and breast carcinoma cell growth by interleukin 4. Cancer Res., 52, 275-279, 1992.
5. Chen, L., Mory, Y., Zilberstein, A. and Revel, M. Growth inhibition of human breast carcinoma and leukemia/lymphoma cell lines by recombinant interferon-b2. Proc. Nat. Acad. Sci., 85, 8037-8041, 1988.
6. Takizawa, H., Ohtoshi, T., Ohta, K., Yamashita, N., Hirohata, S., Hirai, K., Hiramatsu, K. and Ito, K. Growth inhibition of human lung cancer cell lines by interleukin 6 in vitro: a possible role in tumor growth via an autocrine mechanism. Cancer Res., 53, 4175-4181, 1993.
7. Danforth, D.N. Jr. and Sgagias, M.K. Interleukin 1 alpha and interleukin 6 act additively to inhibit growth of MCF-7 breast cancer cells in vitro. Cancer Res., 53, 1538-1545, 1993.
8. Raitano, A.B. and Kore, M. Growth inhibition of a human colorectal carcinoma cell line by interleukin 1 is associated with enhanced expression of gamma-interferon receptors. Cancer Res., 53, 636-640, 1993.
9. Totpal, K. and Aggarwal, B.B. Interleukin 4 potentiates the antiproliferative effects of tumor necrosis factor on various tumor cell lines. Cancer Res., 51, 4266-4270, 1991.
10. Kishimoto, T., Akira, S. and Taga, T. Interleukin 6 and its receptor: a paradigm for cytokines. Science, 258, 593-597, 1992.
11. Cimoli, G., Russo, P., Billi, G., Mariani, G.L., Rovini, E. and Venturing M. Human granulocyte - macrophage colony - stimulating factor is a growth factor active on human ovarian cancer cells. J. Cancer Res., 82, 1196-1198, 1991.
12. Motro, B., Itin, A., Sachs, L. and Keshet, E. Pattern of interleukin 6 gene expression in vivo suggests a role for this cytokine in angiogenesis. PNAS, 87, 3092-3096, 1990.
13. Miki, S., Iwano, M., Miki, Y., Yamamoto, M., Tang, B., Yokokawa, K., Sonoda, T., Hirano, T. and Kishimoto, T. IL6 functions as an autocrine growth factor in renal cell carcinoma. FEBS Lett., 250, 607-610, 1989.
14. Van Meir, E., Sawamura, Y., Diserens, A.C., Hamou, M.F. and de Tribolet, N. Human glioblastoma cells release interleukin 6 in vivo and in vitro. Cancer Res., 50, 6683-6688, 1990.
15. Erroi, A., Sironi., M., Chiaffarino, F., Guo, C.Z., Mengozzi, M. and Mantiovani, A. IL1 and IL6 release by tumor associated macrophages from human ovarian carcinoma. Int. J. Cancer, 44, 795-801, 1989.
16. Klein, B., Zhang, X.G., Jourdan, M., Content, J., Houssiau, F., Aarden, L., Piechaczyk, M. and Bataille, R. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin 6. Blood, 73, 517-526, 1989.
17. Wu, S., Rodabaugh, K., Martinez-Maza, O., Watson, J.M., Silverstein, D.S., Boyer, C.M., Peters, W.P., Weinberg, B., Berek, J.S. and Bast, R.C. Jr. Stimulation of ovarian tumor cell proliferation with monocyte products including interleukin 1, interleukin 6 and tumor necrosis factor a. Am. J. Obst. Gynecol., 166, 997-1007, 1992.
18. De waal Malefyt, R., Abrams, J., Bennett, B., Figdor, C.G. and De Vries, J.E. Interleukin 10 inhibits cytokine synthesis by human monocytes: an autoregulatory role of ILlO produced by monocytes. J. Exp. Med., 174, 1209-1220, 1991.
19. Matsuda, M., Salazar, F., Petersson, M., Masucci, G., Hansson, J., Pisa, P., Zhang, Q.J., Masucci, M.G. and Kiessling, R. Interleukin 10 pretreatment protects target cells from tumor and allospecific cytotoxic T cells and down regulates HLA class I expression. J. Exp. Med., 180, 2371-2376, 1994.
20. Hiscox, S., Hallett, M.B., Puntis, M.C. and Jiang, W.G. Inhibition of cancer cell motility and invasion by interleukin 12. Clin. Exp. Metast., 5, 396-404, 1995.
21. Tamm, I., Cardinale, I., Krueger, J., Murphy, J.S., May, L.T. and Sehgal, P.B. Interleukin 6 decreases cell-cell association and increases motility of ductal breast carcinoma cells. J. Exp. Med., 170, 1649-1669, 1989.
22. Welch, D.R., Fabra, A. and Nakajima, M. Transforming growth factor β stimulates mammary adenocarcinoma cell invasion and metastatic potential. Proc. Nat. Acad. Sci., 87, 7678-7682, 1990.
23. Arrick, B.A., Lopez, A.R., Elfman, F., Ebener, R., Damsky, C.H. and Derynck, R. Altered metabolic and adhesive properties and increased tumorigenesis associated with increased expression of transforming growth factor β1. J. Cell. Biol., 118, 715-726, 1992.
24. Krasagakis, K., Garbe, C., Zouboulis, C.C. and Orfanos, C.E. Growth control of melanoma cells and melanocytes by cytokines. Recent Results in: Cancer Res., 139, 169-182, 1995.
25. Lu, C., Vickers, M.F. and Kerbel, R.S. Interleukin 6: a fibroblast derived growth inhibitor of human melanoma cells from early but not advanced stages of tumor progression- Proc. Nat. Acad. Sci., 89, 9215-9219, 1992.
26. Woodworth, C.D., McMullin, E., Iglesias, M. and Plowman, G.D. Interleukin 1 alpha and tumor necrosis factor alpha stimulate autocrine amphiregulin expression and proliferation of human papillomavirus-immortalized and carcinoma-derived cervical epithelial cells. Proc. Nat. Acad. Sci., 92, 2840-2844, 1995.
27. Bast, R.C. Jr., Boyer, C.M., Jacobs, I., Xu, F.J., Wu, S., Wiener, J., Kohler, M. and Berchuck, A. Cell growth regulation in epithelial ovarian cancer. Cancer, 71, 1597-1601, 1993.
28. Yamaraura, M., Modlin, R.L., Ohmen, J.D. and Moy, R.L. Local expression of anti-inflammatory cytokines in cancer. J. Clin. Invest., 91, 1005-1010, 1993.
29. Nakagomi, H., Pisa, P., Pisa, E.K., Yamamoto, Y., Halapi, E., Backlin, K., Juhlin, C. and Kiessling, R. Lack of interleukm 2 (IL2) expression and selective expression of ILlO mRNA in human renal cell carcinoma. Int. J. Cancer, 63, 366-371, 1995.
30. Lüscher, U., Fihjueira, L., Juretic, A., Zuber, M., Lüscher, N.J., Heberer, M. and Spagnoli, G. The pattern of cytokine gene expression in freshly excised human metastatic melanoma suggests a state of reversible anergy of tumor-infiltrating lymphocytes. Int. J. Cancer, 57, 612, 1994.
31. Tartour, E., Gey, A., Sastre-Garau, X., Pannetier, C., Mosseri, V., Kourilsky, P. and Fridman, W.H. Analysis of interleukin 6 gene expression in cervical neoplasia using a quantitative polymerase chain reaction assay: evidence for enhanced interleukin 6 gene expression in invasive carcinoma. Cancer Res , 54, 6243-6248, 1994.
32. Meyers, F.J., Gumerlock, P.M., Kawasaki, E.S., Wang, A.M., de Vere White, R.W. and Erlich, H.A. Bladder cancer: human leukocyte antigen II, interleukin 6 and interleukin 6 receptor expression determined by the polymerase chain reaction. Cancer, 67, 2087-2095, 1991.
33. Vowels, B.R., Lessin, S.R., Cassin, M., Jaworsky, C., Benoit, B., Wolfe, J.T. and Rook, A.H. TH2 cytokine mRNA expression in skin in cutaneous T cell lymphoma. J. Invest Dermatol., 103, 669-673, 1994.
34. Weng, X., Mathiot, C., Lando, D. and Fridman, W.H. Inhibition of Lak cells by IL2-activated monocytes: role of TGF-β and PGE2. The Cancer Journal, 4, 307-315, 1991.
35. Matsuda, M., Salazar, F., Petersson, M., Masucci, G., Hansson, J., Pisa, P., Zhang, Q.J., Masucci, M.G. and Kiessling, R. Interleukin 10 pretreatment protects target cells from tumor- and allo-specific cytotoxic T cells and downregulates HLA class I expression. J. Exp. Med., 180, 6, 2371-2376, 1994.
36. Miescher, S., Whiteside, T.L., Carrel, S. and von Fliedner, V. Functional properties of tumor infiltrating and blood lymphocytes in patients with solid tumors: effect of tumor cells and their supernatants on proliferative responses of lymphocytes. J. Immunol., 136, 1899-1907, 1986.
37. Tartour, E., Latour, S., Mathiot, C., Thiounn, N., Mosseri, V., Joyeux, I., Dubois d'Enghien, C., Lee, R., Debre, B. and Fridman, W.H. Variable expression of CD3-z chain in tumor-infiltrating lymphocytes (TIL) derived from renal-cell carcinoma: relationship with TIL phenotype and function. Int. J. Cancer, 63, 205-212, 1995.
38. Vitolo, D., Zerbe, T., Kanbour, A., Dahl, C., Herberman, R.B. and Whiteside, T. Expression of mRNA for cytokines in tumor-infiltrating mononuclear cells in ovarian adenocarcinoma and invasive breast cancer. Int. J. Cancer, 51, 573-580, 1992.
39. Lüscher, U., Filgueira, L., Juretic, A., Zuber, M., Lüscher, N.J., Heberer, M. and Spagnoli, G. The pattern of cytokine gene expression in freshly excised human metastatic melanoma suggests a state of reversible anergy of tumor-infiltrating lymphocytes. Int. J. Cancer, 57, 612-619, 1994.
40. Roszman, T., Elliott, L. and Brooks, W. Modulation of T-cell function by gliomas. Immunol. Today, 12, 370-374, 1991.
41. Reinhold, U., Abken, H., Kukel, S., Goeden, B., Uerlich, M., Neumann, U. and Kreysel, H.W. Tumor-infiltrating lymphocytes isolated from a Ki-1-positive large cell lymphoma of the skin. Cancer, 68, 2155-2160, 1991.
42. Erroi, A., Sironi, M., Chiaffarino, F., Guo, C.Z., Mengozzi, M. and Mantovani, A. IL1 and IL6 release by tumor associated macrophages from human ovarian carcinoma. Int. J. Cancer, 44, 795-801, 1989.
43. Beissert, S., Bergholz, M., Waase, I., Lepsien, G., Schauer, A., Pfizenmaier, K. and Koronke, M. Regulation of tumor necrosis factor gene expression in colorectal adenocarcinoma: in vivo analysis by in situ hybridization. Proc. Nat. Acad. Sci., 86, 5064-5068, 1989.
44. Tartour, E., Pannetier, C., Mathiot, C., Teillaud, J.L., Sautes, C., Kourilsky, P. and Fridman, W.H. Prognostic value of cytokine and soluble Fcγ receptor assays in oncology. Immunol. letter, 44, 145-148, 1995.
45. Blay, J.Y., Burdin, N., Rousset, F., Lenoir, G., Biron, P., Philip, T., Banchereau, J. and Favrot, M. Serum interleukin 10 in non-Hodgkin's lymphoma: a prognostic factor. Blood, 82, 2169-2174, 1993.
46. Nakazaki, H. Preoperative and postoperative cytokines in patients with cancer. Cancer, 70, 709-713, 1992.
47. Gorsch, S.M., Memoh, V.A., Stukel, T.A., Gold, L.I. and Arrick, B.A. Immunohistochemical staining for transforming growth factor beta 1 associates with disease progression in human breast cancer. Cancer Res., 52, 24, 6949-6952, 1992.
48. Okamoto, T., Watanabe, N., Yamauchi, N., Tsuji, Y., Tsuji, N., Itoh, Y., Neda, H. and Niitsu, Y. Endogenous tumor necrosis factor exerts its protective function intracellularly against the cytotoxicity of exogenous tumor necrosis factor. Cancer Res., 52, 5278-5281, 1992.
49. Spriggs, D., Imamura, K., Rodriguez, C., Horiguchi, J. and Kufe, D.W. Induction of tumor necrosis factor expression and resistance in a human breast tumor cell line. Proc. Nat. Acad. Sci., 84, 6563-6566, 1987.
50. Lu, C. and Kerbel, R.S. Interleukin 6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression. J. Cell. Biol., 120, 1281-1288, 1993.
51. Blay, J.Y., Negrier, S., Combaret, V., Attali, S., Goulot, E., Mezrrouche, Y., Mercatello, A., Ravault, A., Tourani, J.M., Moskovtchenko, J.F., Philip, T. and Favrot, M. Serum levels of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res., 52, 3317-3322, 1992.
52. Tartour, E., Dorval, T., Mosseri, V., Deneux, L., Mathiot, C., Brailly, H., Montero, F., Joyeux, I., Pouillart, P. and Fridman, W.H. Serum interleukin 6 and C reactive protein levels correlate with resistance to IL2 therapy and poor survival in melanoma patients. Br. J. Cancer, 69, 911-913, 1994.
53. Herrmann, F., Helfrich, S.G., Lindemann, A., Schleiermacher, E., Huber, C. and Merstelmann, R. Elevated circulating levels of tumor necrosis factor predict unresponsiveness to treatment with interferon alfa-2b in chronic myelogenous leukemia. J. Clin. Oncol., 10, 631-634, 1992.
54. Mizutami, Y., Bonavida, B., Koishihara et al. Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum (II) by anti-interleukin 6 moniclonal antibody or anti-interleukin 6 receptor monoclonal antibody. Cancer Res., 55, 590-596, 1995.
55. Borsellino, N., Belldegrun, A. and Bonavida, B. Endogenous interleukin 6 is a resistance factor for cis-Diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. Cancer Res., 55, 4633-4639, 1995.
56. Scambia, G., Testa, U., Panici, P.B., Martcucci, R., Foti, E., Petrini, M., Amoroso, M., Masciullo, V., Peschle, C. and Mancuso, S. Interleukin 6 serum levels in patients with gynecological tumors. Int. J. Cancer, 57, 318-323, 1994.
57. Yoneda, T., Nakai, M., Moriyama, K., Scott, L., Ida, N., Kunitomo, T. and Mundy, G.R. Neutralizing antibodies to human interleukin 6 reverse hypercalcemia associated with a human squamous carcinoma. Cancer Res., 53, 737-740, 1993.
58. Weissglas, M., Schamhart, D., Lowik, C., Papapoulos, S., Vos, P. and Kurth, K.H. Hypercalcemia and cosecretion of interleukin 6 and parathyroid hormone related peptide by human renal cell carcinomas implanted into nude mice. J. Urology, 153, 854-857, 1995.
59. Yoneda, T., Alsina, M.M., Chavez, J.B., Bonewald, L., Nishimura, R. and Mundy, G. R. Evidence that splenic tumor necrosis factor plays a pathogenetic role in the paraneoplastic syndromes of cachexia, hypercalcemia and leukocytosis in a human tumor in nude mice. J. Clin. Invest., 87, 977-985, 1991.
60. Blay, J.Y., Favrot, M., Rossi, J.F. and Wijdenes, J. Role of interleukin 6 in paraneoplastic thrombocytosis. Blood, 87, 2261-2262, 1993.
61. Tartour, E., Adams, D., Besancenot, J.F., Fridman, W.H. and Schhimberger, M. Poems syndrome with high interleukin (IL)6 and IL1β serum levels, in a patient with thyroid carcinoma and melanoma. Eur. J. Cancer, 30A, 894-895, 1994.
62. Keller, U. Pathophysiology of cancer cachexia. Supportive Care in Cancer, 6, 290-294, 1993.
63. Greenberg, A.S., Nordan, R.P., McIntosh, J., Calvo, J.C., Scow, R.O. and Jablons, D. Interleukin 6 reduces lipoprotein lipase activity in adipose tissue of mice in vivo and in 3T3-L1 adipocytes: a possible role for interleukin 6 in cancer cachexia. Cancer Res., 52, 4113-4116, 1992.
64. Mule, J.J., Yang, J.C. and Lafreniere, R. Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high dose recombinant interleukin 2. J. Immunol., 139, 285-294, 1987.
65. Thompson, J.A., Peace, D.J., Klarnet, J.P., Kern, D.E., Greenberg, P.D. and Cheever, M.A. Eradication of disseminated murine leukemia by treatment with high dose interleukin 2. J. Immunol., 137, 3675-3680, 1986.
66. Rosenberg, S.A., Lotze, M.T., Muul, L.M., Leitman, S., Chang, A.E., Ettinghausen, S.E., Matory, Y.L., Skibber, J.M., Shiloni, E., Vetto, J.T., Seipp, C.A., Simpson, C. and Richert, C.M. Observations on the systemic administration of autologous lymphokine activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Eng. J. Med., 313, 1485-1492, 1985.
67. West, W.H., Tauer, K.W., Yannelli, J.R, Aeshall, G.D., Osr, D.W., Thurman, G.B. and Oldham, R.K. Constant infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N. Engl. J. Med., 316, 898-905, 1987.
68. Rosenberg, S.A., Lotze, M.T., Muul, L.M., Chang, A.E., Avis, F.P., Leitman, S., Linehan, M., Robertson, C.N., Lee, R.E., Rubin, J.T., Steipp, C.A., Simpson, C.G. and White, D.E. A progress report on the treatment of 157 patients with advanced cancer using lympholine-activated killer cells and interleukin-2 alone. N. Engl. J. Med., 316, 889-897, 1987.
69. Parkinson, D.R., Abrams, J.F., Wiernik, P.H., Rayner, A.A., Margolin, K.A., Van Echo, D.A., Sznol, M., Dutcher, J.P., Aronson, F.R., Doroshow, J.H., Atkins, M.B. and Hawkins, M.J. Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study. J. CHn. Oncol., 8, 1650-1656, 1990.
70. Rosenberg, S.A. The immunotherapy and gene therapy of cancer. J. Clin. Oncol., 10, 180-199, 1992.
71. Dorval, T., Mathiot, C., Chosidow, O., Revuz, J., Avril, M.F., Guillaume, J.C., Tursz, T., Brandely, M., Pouillart, P. and Fridman, W.H. Phase II trial in metastatic melanoma; analysis of clinical and immunological parameters. Biotechnol. Ther., 3, 63-79, 1992.
72. Legha, S.S., Gianan, M.A., Plager, C., Eton, O.E. and Papadopoulous, N.E. Evaluation of interleukin-2 administered by continuous infusion in patients with metastatic melanoma. Cancer, 77(1), 89-96, 1996.
73. Goedegebuure, P.S., Douville, L.M., Li, H., Richmond, G.C., Schoof, D.D., Scavone, M. and Eberlein, T.J. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study. J. Clin. Oncol., 13(8), 1939-1949, 1995.
74. Rosenberg, S.A., Yannelli, J.R., Yang, J.C., Topalian, S.L., Schwartzentruber, D.J., Weber, J.S., Parkinson, D.R., Seipp, C.A., Einhorn, J.H. and White, D.E. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin-2. J. Nat. Cancer Inst., 86(15), 1159-1166, 1994.
75. Tartour, E., Mathiot, C. and Fridman, W.H. Current status of interleukin 2 therapy in cancer. Biomed & Pharmacother., 46, 473-484, 1992.
76. Atzpodien, J., Körfer, A., Franks, C.R., Poliwoda, H. and Kirchner, H. Home therapy with recombinant interleukin 2 and interferon-a2b in advanced human malignancies. Lancet, 335, 1509-1512, 1990.
77. Thiounn, N., Mathiot, C., Dorval, T., Tartour, E., Mosseri, V., Zerbib, M., Fridman, W.H. and Debre, B. Lack of efficacy of low dose subcutaneous recombinant interleukin 2 and interferon-a in the treatment of metastatic renal cell carcinoma. Br. J. Urology, 75, 586-589, 1995.
78. Yang, J.C., Topalian, S.L., Schwartzentruber, D.J., Parkinson, D.R. and Marincola, F.M. The vise of polyethylene glycol-modified interleukin-2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma. A phase I study and a randomized prospective study comparing IL-2 alone versus IL-2 combined with PEG-IL-2. Cancer, 76(4), 687-694, 1995.
79. Tartour, E., Blay, J.Y., Dorval, T., Escudier, B., Mosseri, V., Douillard, J.Y., Deneux, L., Gorin, I., Negrier, S., Mathiot, C., Pouillart, P. and Fridman, W.H. Predictors of clinical response to interleukin 2-based immunotherapy in melanoma patients: a french multiinstitutional study, J. Clin. Oncol., 14, 1697-1703, 1996.
80. Simpson, W.G., Heys, S.D. and Whiting, P.H. Acute phase proteins and recombinant IL2 therapy: prediction of response and survival in patients with colorectal cancer. Clin. Exp. Immunol., 99, 143-147, 1995.
81. Minasian, L.M., Motzer, R.J., Gluck, L., Mazumdar, M., Vlamis, V. and Krown, S.E. Interferon alpha-2a in advanced renal cell carcinoma. Treatment results and survival m 159 patients with long term follow up. J. Clin. Oncol., 11, 1368-1375, 1993.
82. Marincola, F.M., Withe, D.E., Wise, A.P. and Rosenberg, S.A. Combination therapy with interferon alpha-éa and interleukin-2 for the treatment of metastatic cancer. J. Clin. Oncol., 13, 1110-1122, 1995.
83. Negrier, S., Escudier, B., Lasset, C. et al. The FNCLCC Crecy trial: interleukin-2 (IL2) + Interferon (IFN) is the optimal treatment to induce responses in metastatic renal cell carcinoma. Proc. Ant. Soc. Clin. Oncol., 15, 629, 1996.
84. Pujade-Lauraine, E., Guastalla, J.P., Colombo, N., Devilier, P., François, E., Fumoleau, P., Monnier, A., Nooy, M., Mignot, L., Bugat, R., Marques, C., Mousseau, M., Netter, G., Maloisel, F., Larbaoui, S. and Brandely, M. Intraperitoneal recombinant interferon gamma in ovarian cancer with residual disease at second look laparatomy. J. Clin. Oncol., 14, 343-350, 1996.
85. Meyskens, F.L. Jr., Kopecky, K.J., Taylor, C.W., Noyes, R.D., Tuthill, R.J., Hersh, E.M., Feun, L.G., Doroshow, J.H., Flaherty, L.E. and Sondak, V.K. Randomized trial of adjuvant human interferon gamma versus observation in high risk cutaneous melanoma: a southwest oncology group study. J. Nat. Cancer Inst., 87, 1710-1712, 1995.
86. Kirkwood, J.M. Biological therapy of melanoma. Proc. Amer. Assoc. Cancer Res., 37, 643, 1996.
87. Nastala, C.L., Edington, H.D., McKinney, T.G., Tahara, H., Nalesnik, M.A. and Brunda, M.J. Recombinant IL-12 administration induces tumor regression in association with IFN gamma production. J. Immunol., 153, 1697-1706, 1994.
88. Brunda, M.J., Luistro, L., Warrier, R.R., Wright, R.B., Hubbard, B.R. and Murphy, M. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J. Exp. Med., 178, 1223-1230, 1993.
89. Desai, B.B , Quinn, P.M., Wolitzky, A.G., Mongini, P.K., Chizzonite, R. and Gately, M.K. IL12 receptor. II Distribution and regulation of receptor expression. J. Immunol., 148, 3125-3132, 1992.
90. Trinchieri, G. Interleukin 12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood, 84, 4008-4027, 1994.
91. Wigginton, J.M., Komschlies, K.L., Back, T.C., Franco, J.L., Brunda, M.J. and Wiltrout, R.H. Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma. J. Nat. Cancer Inst., 88, 38-43, 1996.
92. Van Ostade, X., Vandenabeele, P., Everaerdt, B., Loetscher, H., Gentz, R., Brockhaus, M., Lesslauer, W., Tavernier, J., Brouckaert, P. and Fiers, W. Human TNF mutants with selective activity on the p55 receptor. Nature, 361, 266-269, 1993.
93. Mule, J.J., McIntosh, J.K., Jablons, D.M. and Rosenberg, S.A. Antitumor activity of recombinant interleukin 6 in mice. J. Exp. Med., 171, 629-636, 1990.
94. Ravoet, C., De Greve, J., Vandewoude, K., Kerger, J., Sculier, J.P., Lacor, P., Stryckmans, P. and Piccart, M. Tumour stimulating effects of recombinant human interleukin 6. Lancet, 344, 1576-1577, 1994.
95. Flaherty, L.E., Liu, P.Y., Fletcher, W.S. et al. Dacarbazine and out patient interleukin-2 in treatment of metastatic malignant melanoma: a phase II southwest oncology group trial. J. Natl. Cancer Inst., 84, 893-894, 1992.
96. Fiedler, W., Jasmin, C., De Mulder, P.H.M. et al. A phase II study of sequential recombinant interleukin-2 followed by dacarbazine in metastatic melanoma. Eur. J. Cancer, 28, 443-446, 1992.
97. Demchak, P.A., Mier, J.W., Robert, N.J. et al. Interleukin-2 and high-dose cisplatin in patients with metastatic melanoma: a pilot study. J. Clin. Oncol., 9, 1821-1830, 1991.
98. Mitchell, M.S. Chemotherapy in combination with biomodulation: a 5 year experience with cyclophosphamide and interleukin-2. Semin. Oncol., 19 (2 suppl. 4), 80-87, 1992.
99. Flaherty, L.E., Redman, B., Marino, S. et al. High dose dacarbazine and cisplatin alone and combined with outpatient interleukin-2 in metastatic malignant melanoma. Proc. Am. Soc. Clin. Oncol., poster no. 1206, 1992. J. Clin. Oncol., 11, 350, 1992.
100. Veelken, H., Rosenthal, F.M., Schneller, F. et al. Combination of interleukin-2 and interferon-alpha in renal cell carcinoma and malignant melanoma: a phase II clinical trial. Biotechnol. Ther., 3, 1-4, 1992.
101. Kruit, W.H.J., Goey, S.H., Monson, J.R.T. et al. Clinical experience with the combined use of recombinant interleukin-2 (IL2) and interferon alfa-2a (IFN alpha) in metastatic melanoma. Br. J. Haematol., 79, 84s- 86s, 1992.
102. Budd, G.T., Murphy, S., Finke, J. et al. Phase I trial of high-dose bolus interleukin-2 and interferon alfa-2a m patients with metastatic malignancy. J. Clin. Oncol., 10, 804-809, 1992.
103. Rosenberg, S.A., Lotze, M.T., Yang, J.C. et al Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J. Clin. Oncol., 7, 1893-1874, 1989.
104. Khayat, D., Borel, C., Tourani, J.M., Benhammouda, A., Antoine, E., Rixe, O., Vuillemin, E., Bazex, P.A., Thill, L., Franks, R., Auclerc, G., Soubrane, C., Banzet, P. and Weil, M. Sequential chemoimmunotherapy with cisplatin interleukin 2 and interferon alfa-2a for metastatic melanoma. J. Clin. Oncol., 11, 2173-2180, 1993.
105. Richards, J.M., Metha, N., Ramming, K. and Skosey, P. Sequential chemoimmunotherapy for metastatic melanoma. J. Clin. Oncol., 10, 1338-1343, 1992.
106. Legha, S.A., Plager, C., Ring, S. et al. A phase II study of biochemotherapy using interleukin-2 + interferon alpha-2a in combination with cisplatin, vinblastine and DTIC in patients with metastatic melanoma. Proc. Am. Soc. Clin. Oncol., poster no. 1179, 1992. J. Clin. Oncol., 11, 343, 1992.
107. Atkins, M.B., O'Boyle, K.R., Sosman, J.A., Weiss, G.R., Margolin, K.A., Ernest, M.L., Kappler, K., Mier, J.W., Sparano, J.A. and Fisher, R.I. Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma. J. Clin. Oncol., 12, 1553-1560, 1994.
108. Atzpodien, J., Lopez-Hanninen, E., Kirchner, H., Franzke, A. and Korfer, A. Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen. Eur. J. Cancer, 31A, 876-881, 1995.
109. Merluzzi, V.J., Weite, K. and Savage, D.M. Expansion of cyclophosphamide-resistant cytotoxic precursors in vitro and in vivo by purified human interleukin 2. J. Immunol., 131, 806-809, 1983.
110. Dorval, T., Negrier, S., Chevreau, C., Baume, D., Cupissol, D., Oskam, R., De Peuter, M.A., Herrera, A. and Escudier, B. Results of a French multicentric randomized trial of chemoimmunotherapy. Proc. Am. As. Soc. Clin. Oncol., 13, 395, 1994.
111. Lippman, S.M., Parkinson, D.R., Itri, L.M., Weber, R.S., Stimson, P., Schantz, S.P., Ota, D.M., Schusterman, M.A., Krakoff, I.H., Gutterman, J. and Ki Hong, W. 13-cis-retinoic acid and interferon alpha-2a. Effective combination therapy for advanced squamous cell carcinoma of the skin. J. Nat. Cancer Instit., 84, 235-241, 1992.
112. Motzer, R.J., Schwartz, L., Murray, L.T., Murphy, B.A., Hoffman, A.D., Albino, A.P., Vlamis, V. and Nanus, M.D. Interferon alpha-2a and 13-cis-retinoic acid in renal cell carcinoma: antitumor activity in a phase II trial and interactions in vitro. J. Clin. Oncol., 13, 1950-1957, 1995.
113. Lopez-Hanninen, E., Kirchner, H. and Atzpodien, J. Interleukine-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. J. Urol., 155, 19-25, 1996.
114. Suzuki, H., Yasukawa, K., Saito, T., Goitsuka, R., Hasegawa, A., Ohsugi, Y., Taga, T. and Kishimoto, T. Anti-human interleukin-6 receptor antibody inhibits human myeloma growth in vivo. Eur. J. Immunol., 22, 1989-1993, 1992.
115. Bataille, R., Barlogie, B., Lu, Z.Y., Rossi, J.F., Lavabre-Bertrand, T., Beck, T., Wijdenes, J., Brochier, J. and Klein, B. Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood, 86, 685-691, 1995.
116. Beck, J.T., Hsu, S.M., Wijdenes, J., Bataille, R., Klein, B., Vesole, D., Hayden, K., Jagannath, S. and Barlogie, B. Alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N. Engl. J. Med., 330, 602-605, 1994.
117. Trojan, J., Johnson, T.R., Rudin, S.D., Illan, J., Tykocinski, M.L. and Lian, J. Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor IRNA. Science, 259, 94-97, 1993.
118. Seung, L.P., Rowley, D.A., Dubey, P. and Schreiber, H. Synergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection. Proc. Nat. Acad. Sci. USA, 92, 6254-6258, 1995.
119. Schmidt, W., Schweighoffer, T., Herbst, E., Maass, G., Berger, M., Schilder, F., Schaffner, G. and Birnstiel, M.L. Cancer vaccines: the interleukin 2 dosage effect. Proc. Nat. Acad. Sci. USA, 92, 4711-4714, 1995.
120. Fearon, E.R., Pardoll, D M., Itaya, T., Golumbeck, P., Levitsky, H.I., Simons, J.W., Darasuyama, H., Vogelstein, B. and Frost, P. Interleukin 2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell, 60, 397-403, 1990.
121. Schmidt-Wolf, G.D. and Schmidt-Wolf Ingo, G.H. Cytokines and gene therapy. Immunol. Today, 16, 173-175, 1995.
122. Golumbek, P., Lazenby, A., Levitsky, H., Jaffee, E., Karasuyama, H., Kaker, M. and Pardoll, D. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science, 254, 713-716, 1991.
123. Lotze, M.T., Rubin, J.T., Carty, S., Edington, H., Ferson, P., Landreneau, R., Pippin, B., Posner, M., Rosenfelder, D. and Watson, C. Gene therapy of cancer: a pilot study of IL-4-gene-modified fibroblasts admixed with autologous tumor to elicit an immune response. Human Gene Ther., 5, 41-55, 1994.
124. Unterhuber, R. Gene therapy gaters speed in Germany. Nature, 365, 197, 1993.
125. Golumbek, P., Azhari, R., Jaffee, E.M., Levitsky, H.I., Lazenby, A., Leong, K. and Pardoll, D. Controlled release biodegradable cytokine depots: a new approach in cancer vaccine design. Cancer Res., 53, 5841-5844, 1993.
126. Roth, C., Mir, L.M., Cressent, M., Quintin-Colonna, F., Belehradek, J., Ley, V., Fradelizi, D. and Kourilsky, P. Inhibition de la croissance tumorale induite par l'injection de cellules histo-incompatibles produisant de l'interleukine 2. Cr. Acad. Sci. Paris, 314, Série III, 499-504, 1992.
127. Becker, J.C., Pancook, J.D., Gillies, S.D., Mendelsohn, J. and Reisfeld, R.A. Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins. Proc. Nat. Acad. Sci. USA, 93, 2702-2707, 1996.
128. Boon, T., Cerottini, J.C., Van den Eynde, B., Van der Bruggen, P. and Van Pal, A. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol., 12, 337-365, 1994.
129. Noguchi, Y., Richards, E., Chen, Y.T. and Old, L.J. Influence of interleukin 12 on p53 peptide vaccination against established meth A sarcoma. Proc. Nat. Acad. Sci., 92, 2219-2223, 1995.
130. Chen, T., Tao, M.H. and Levy, R. Idiotype-cytokine fusion proteins as cancer vaccines. Relative efficacy of IL2, IL4 and granulocyte-macrophage colony stimulating factor. J. Immunol., 153, 4775-4787, 1995.